Chronic Plantar Fasciitis

2
Pipeline Programs
2
Companies
2
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Ipsen
DYSPORTApproved
botulinum toxin type a
Ipsen
Acetylcholine Release Inhibitor [EPC]injection2009

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
1
1
Botulinum toxin type APhase 2/31 trial
Active Trials
NCT00447876Completed40Est. Apr 2009
Arthrex
ArthrexCA - Santa Barbara
1 program
ACPN/A1 trial
Active Trials
NCT01614223UnknownEst. Sep 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenBotulinum toxin type A
ArthrexACP

Clinical Trials (2)

Total enrollment: 40 patients across 2 trials

NCT00447876IpsenBotulinum toxin type A

Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis

Start: Jul 2005Est. completion: Apr 200940 patients
Phase 2/3Completed

Autologous Conditioned Plasma (ACP) for Patients With Plantar Fasciitis

Start: Sep 2010Est. completion: Sep 2015
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space